Presage Biosciences, Millennium sign cancer research agreement

As per the agreement, Millennium will have access to Presage’s technology platform to enable non-clinical identification of effective oncology drug combinations in solid tumors.

Presage is eligible to receive upfront fees, research funding and development and regulatory milestones associated with the identification of drug combinations.

The technology platform allows for the comparison of multiple drugs in the same tumor within a preclinical model.

Millennium chief scientific officer Joseph Bolen said: "Presage’s technology platform allows us to obtain in-depth non-clinical in vivo data that is typically difficult to gather by conventional approaches."